Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco PBM Branding Campaign Features “Education” On Contract Practices

This article was originally published in The Pink Sheet Daily

Executive Summary

The “Extra Strength Solutions” campaign is launching at a time when the “transparency” of pharmacy benefit managers’ client contracts is being questioned. The corporate branding effort kicked off with newspaper ads, to be followed by Medco-sponsored symposiums.

You may also be interested in...



PBM Competition, Not Regulation, Will Ensure Rx Savings, FTC/DoJ Say

Marketplace forces will encourage pharmacy benefit managers to offer their best price and service combination, as well as provide greater disclosure of rebate information, a joint report by the Federal Trade Commission and Justice Department states.

PBM Competition, Not Regulation, Will Ensure Rx Savings, FTC/DoJ Say

Marketplace forces will encourage pharmacy benefit managers to offer their best price and service combination, as well as provide greater disclosure of rebate information, a joint report by the Federal Trade Commission and Justice Department states.

PBM Disclosure, Fiduciary Responsibility Bills Would Increase Rx Costs 10%, PCMA Says

A report released by the PBM trade association outlines the negative impact various PBM-targeted legislative proposals would have on Rx spend. PCMA says PBMs reduce drug costs 25%, and will save Medicare $53 bil. in 2005.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel